<DOC>
	<DOCNO>NCT01217112</DOCNO>
	<brief_summary>This 15-19 week study conduct GW Pharma Ltd pilot study order determine efficacy safety two cannabinoids : GWP42004 GWP42003 alone , combination patient Type 2 diabetes . This first study determine whether study medication positive benefit subject cholesterol level , body weight , liver fat content metabolic parameter compare placebo medication .</brief_summary>
	<brief_title>GWMD1092 - GWP42003 : GWP42004 Together Plus Alone Type II Diabetes</brief_title>
	<detailed_description>In study 1-5 week baseline period follow 13 week treatment period , one week follow-up . Eligible subject enter study screen visit ( Visit 1 ) return randomisation ( Visit 2 , Day 1 ) . At discretion investigator ( base individual subject ) , Visit 1 could split two separate visit ( Visits 1A B ) allow 21-day washout period prohibit medication prior blood sample eligibility . Further outpatient study visit ( assessment purpose ) take place study site end Week 4 treatment ( Visit 3 , Day 29 ) , overall end treatment Week 13 ( Visit 5 , Day 92 ) . A telephone assessment also perform Day 57 ( Visit 4 ) Week 14 ( Visit 6 , Day 99 ) safety follow-up purpose . During 13 week randomise treatment phase , subject receive blinded , oral dos allocate randomised treatment twice daily . Treatment self-administered outpatient basis , morning even 13 week . Subjects instructed time study medication 30 minute breakfast even meal . Physical metabolic parameter assess , treatment evaluate clinical response . Diabetic dyslipidaemic medication usage ( applicable ) , appetite 0-10 NRS data collect daily treatment period , use study diary .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<criteria>Clinically diagnose Type 2 diabetes , residual islet cell function ; Diet control receive oral antidiabetic treatment ( metformin biguanides and/or sulphonyl urea ) receive stable dose least 3 month prior enrollment ; High Density Lipoprotein cholesterol ≤ 1.3mmol/L ( female ) , ≤ 1.2mmol/L ( male ) ; Glycosylated haemoglobin level ≤ 10 % ; Triglycerides ≤ 10mmol/L ; Willing maintain stable dose oral antidiabetic and/or lipidlowering agents/medications may effect plasma/serum glucose , insulin lipid parameter duration study , applicable ; No change diet exercise four week prior subject agrees keep stable duration study ( opinion investigator ) ; Subject take insulin ( i.e . insulindependent ) ; Taking follow category medicine : fibrates , Thiazolidinediones , therapeutic Omega3 fatty acid , alphaglucosidase inhibitor unwilling abstain duration study ; Currently use use recreational cannabis , medicinal cannabis , cannabinoid medication ( include Sativex® ) , synthetic cannabinoid base medication within 30 day prior study entry unwilling abstain duration study ; Any know suspected history : alcohol substance abuse epilepsy recurrent seizure ; Any know suspected history depression sufficient require treatment antidepressant disrupt ordinary life discretion investigator ) ; Subject significant history anxiety , suicidal ideation selfharm ; Clinically significant cardiac , renal hepatic impairment opinion investigator ; Genetic dyslipidaemic condition opinion investigator ; Currently take lipid lower agent stable dose maintain least four week randomisation ( Visit 2 ) ; Female subject , pregnant , lactate plan pregnancy course study three month date last dose ; Female subject child bear potential unless willing use two form contraception , one must barrier contraception ( e.g . female condom occlusive cap ( diaphragm cervical vault/caps ) spermicide ) study three month thereafter ; Male subject whose partner child bear potential , unless willing use appropriate barrier method contraception ( condom spermicide ) addition female partner use another form barrier contraception ( e.g . female condom occlusive cap ( diaphragm cervical vault/caps ) spermicide ) study three month thereafter ; Body weight &gt; 150kg ; Travel outside country residence plan study ; Currently receive prohibit medication unwilling stop screen visit duration study ; Received unapproved Investigational Medicinal Product ( IMP ) within 30 day screen visit ; In opinion investigator , consider suitable study ; Any know suspected hypersensitivity cannabinoids excipients IMP ( ) ; Any significant disease disorder , opinion investigator , may either put subject risk participation study , may influence result study , subject 's ability participate study ; Has postural drop ≥ 20 mmHg systolic blood pressure Visit 1 ; Any abnormality identify physical exam Visit 1 opinion investigator , would prevent subject safe participation study ; Unwilling abstain donation blood study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Dyslipidemias</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Liver Fat</keyword>
	<keyword>Body Fat</keyword>
</DOC>